Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor
TM Foy, J Bannink, RA Sutherland, PD McNeill… - Vaccine, 2001 - Elsevier
TM Foy, J Bannink, RA Sutherland, PD McNeill, GG Moulton, J Smith, MA Cheever…
Vaccine, 2001•ElsevierThe present study utilizes an in vivo murine tumor expressing human Her-2/neu to evaluate
potential Her-2/neu vaccines consisting of either full length or various subunits of Her-2/neu
delivered in either protein or plasmid DNA form. Our results demonstrate that protective
immunity against Her-2/neu-expressing tumor challenge can be achieved by vaccination
with plasmid DNA encoding either full length or subunits of Her-2/neu. Partial protective
immunity was also observed following vaccination with the intracellular domain (ICD), but …
potential Her-2/neu vaccines consisting of either full length or various subunits of Her-2/neu
delivered in either protein or plasmid DNA form. Our results demonstrate that protective
immunity against Her-2/neu-expressing tumor challenge can be achieved by vaccination
with plasmid DNA encoding either full length or subunits of Her-2/neu. Partial protective
immunity was also observed following vaccination with the intracellular domain (ICD), but …
The present study utilizes an in vivo murine tumor expressing human Her-2/neu to evaluate potential Her-2/neu vaccines consisting of either full length or various subunits of Her-2/neu delivered in either protein or plasmid DNA form. Our results demonstrate that protective immunity against Her-2/neu-expressing tumor challenge can be achieved by vaccination with plasmid DNA encoding either full length or subunits of Her-2/neu. Partial protective immunity was also observed following vaccination with the intracellular domain (ICD), but not extracellular domain (ECD), protein subunit of Her-2/neu. The mechanism of protection elicited by plasmid DNA vaccination appeared to be exclusively CD4 dependent, whereas the protection observed with ICD protein vaccination required both CD4 and CD8 T cells.
Elsevier